™'s David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest 

 (triamcinolone acetonide injectable suspension) for  the treatment of macular edema associated with uveitis. 

XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.

The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.

Videos

News

Conference

Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Modern Retina® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the retinal and ophthalmic communities.

Expert Interviews

Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health.

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis. 

Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb